Gkotinakou IM, Befani C, Simos G, Liakos P (2019) ERK1/2 phosphorylates HIF-2α and regulates its activity by controlling its CRM1-dependent nuclear shuttling. J Cell Sci 132 30962349

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S672-p - HIF2A (human) ▲

Modsite: APLGPPVsPPHVSTF SwissProt Entrez-Gene Orthologous residues HIF2A (human): S672‑p, HIF2A (mouse): A676‑p, HIF2A (rat): T676‑p Characterization Methods used to characterize site in vivo:  [32P] ATP in vitro, immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  liver cancer, hepatocellular carcinoma Relevant cell lines - cell types - tissues:  E.coli (bacterial), HeLa (cervical), Huh7 (hepatic) Cellular systems studied:  cell lines Species studied:  bacteria, human Enzymes shown to modify site in vitro:  Type Enzyme KINASE ERK2 (human) KINASE ERK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes U0126 decrease Downstream Regulation Effect of modification (function):  intracellular localization, molecular association, regulation Effect of modification (process):  transcription, induced Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Exportin-1 (human) Disrupts co-immunoprecipitation Comments:  inhibition of CRM1-dependent nuclear export